Latest filing published 06 Jul 2018 for Spero Therapeutics, Inc., €10k.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- -27.2%Entry US$12.61 · Close at T+365 US$9.18
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Joel Sendek: trading record in brief
Joel Sendek is a declared insider of Spero Therapeutics, Inc., with filings sourced from SEC (Form 4). Over a trading history stretching from 6 November 2017 to 5 July 2018, the count stands at 4 filings.
In open-market terms, that means 1 purchase worth €60k on one side and 1 sale worth €30k on the other. On balance, insiders were net buyers of €30k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 1 option exercise. So far in 2018, the count stands at no purchases and 1 sale.
On 6 July 2018 came the latest disclosure, an option exercise for €10k in Spero Therapeutics, Inc. The last insider purchase was made public on 7 November 2017, 3,289 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Joel Sendek
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 2,000 shares@ US$5.9010.1% of flowCommon StockSEC:0000899243-18-019567:0
- 2,000 shares@ US$17.5029.8% of flowCommon StockSEC:0000899243-18-019567:1
- 10,181 sharesCommon StockSEC:0000899243-17-025507:0
- 5,000 shares@ US$14.0060.1% of flowCommon StockSEC:0000899243-17-025507:1Canonical exit: 4 Feb 2018 (T+90)
4 of 4 declarations